-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
HANGZHOU AND SHAOXING, March 15, 2022 /PRNewswire/ -- Ascletis Pharma Co.
Based on a series of optimization measures, the production cost of ASC10 has dropped significantly, which is critical to the availability of anti-COVID-19 drugs
1.
2.
3.
The latest experimental data show that ASC10-A has potent cellular-level resistance to the Omicron variant (EC50 = 0.
ASC10 is an oral dual prodrug of the antiviral nucleoside analog ASC10-A, which has a potent inhibitory effect on novel coronavirus polymerase (RdRp)
So far, Ascletis has filed a number of patent applications for ASC10 and its uses worldwide
About Song Li
Ascletis is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.
1.
2.
3.
4.
Source: Ascletis Pharma Co.